PharmaTher announces sale of Ketamine ANDA

* PharmaTher Holdings (OTCQB:PHRRF [https://seekingalpha.com/symbol/PHRRF]) said on Wednesday that it has entered into a definitive Asset Purchase Agreement [https://seekingalpha.com/pr/20250665-pharmather-announces-sale-of-ketamine-anda-with-potential-to-generate-over-us-25-million-in] for the sale of its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical company specializing in sterile injectables and complex generics.
* Under the terms of the agreement, PharmaTher will receive a confidential upfront cash payment at closing and is eligible for milestone payments based on cumulative sales thresholds, along with ongoing profit-sharing for a period of seven years following the first commercial sale.
* In total, the agreement contemplates potential consideration of more than US$25M; however, there can be no assurance that any or all of these payments will be realized, as they are contingent on the product’s commercial performance.

MORE ON PHARMATHER HOLDINGS

* Financial information for PharmaTher Holdings  [https://seekingalpha.com/symbol/PHRRF/income-statement]